Research programme: retinitis pigmentosa therapeutics - Asklepios

Drug Profile

Research programme: retinitis pigmentosa therapeutics - Asklepios

Alternative Names: BNP-RP

Latest Information Update: 16 Jan 2017

Price : $50

At a glance

  • Originator Asklepios BioPharmaceutical
  • Developer Asklepios BioPharmaceutical; ForSight VISION4
  • Class Gene therapies
  • Mechanism of Action Gene transference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Retinitis pigmentosa

Most Recent Events

  • 10 Jan 2017 ForSight VISION4 has been acquired by and merged into Roche
  • 16 Jul 2016 No recent reports of development identified for research development in Retinitis-pigmentosa in USA (Parenteral)
  • 25 Sep 2012 Early research in Retinitis pigmentosa in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top